BlockBeats News, December 23: According to Ash (@ahboyash), out of the 118 new coins from 2025 TGE, 84.7% (100/118) of tokens have an FDV lower than the FDV at TGE. This means that approximately 4 out of every 5 newly issued tokens currently have an FDV lower than their issuance valuation. The median FDV of these tokens has dropped by 71% compared to issuance (median market cap drop of 67%). Only 15% of tokens have seen an increase in FDV compared to TGE.
At the bottom of the performance list, there are 15 tokens with a decline of over 90%, including some notable projects such as Berachain (-93%), Animecoin (-94%), and Bio Protocol (-93%).
Overall, the total FDV of these tokens has compressed from the initial $139 billion at listing to the current $54 billion, meaning that approximately $87 billion (59%) of the "on-paper" FDV has evaporated (this calculation does not include projects that have gone to zero).
There are also outstanding performers, mostly projects launched in the second half of 2025 with lower initial valuations, including Aster (+745%), Yooldo Games (+538%), and Humanity (+323%).
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.